Nurix Therapeutics Inc Ordinary Shares NRIX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NRIX is a good fit for your portfolio.
News
-
Nurix Therapeutics Shares Climb 19% on Extended Sanofi Collaboration
-
Nurix Therapeutics, Gilead Sciences Extend Strategic Collaboration
-
Nurix Therapeutics: FDA Lifts Partial Clinical Hold on NX-2127 Study
-
Nurix Therapeutics Gets FDA Fast-Track Designation for NX-5948
-
Nurix Therapeutics Says FDA Places Partial Clinical Hold on NX-2127 Phase 1 Trial
Trading Information
- Previous Close Price
- $21.04
- Day Range
- $21.23–22.20
- 52-Week Range
- $4.22–24.38
- Bid/Ask
- $21.51 / $21.97
- Market Cap
- $1.41 Bil
- Volume/Avg
- 590,612 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 19.93
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 284
- Website
- http://www.nurixtx.com
Comparables
Valuation
|
Metric
|
NRIX
|
IGMS
|
PRLD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.81 | 4.09 | 1.51 |
Price/Sales | 19.93 | 298.61 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
NRIX
IGMS
PRLD
Financial Strength
|
Metric
|
NRIX
|
IGMS
|
PRLD
|
|---|---|---|---|
Quick Ratio | 5.49 | 7.75 | 11.44 |
Current Ratio | 5.57 | 7.98 | 11.64 |
Interest Coverage | — | — | — |
Quick Ratio
NRIX
IGMS
PRLD
Profitability
|
Metric
|
NRIX
|
IGMS
|
PRLD
|
|---|---|---|---|
Return on Assets (Normalized) | −37.66% | −45.69% | −39.87% |
Return on Equity (Normalized) | −56.12% | −90.75% | −44.79% |
Return on Invested Capital (Normalized) | −55.89% | −81.91% | −43.35% |
Return on Assets
NRIX
IGMS
PRLD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Fpqxhqfrtm | Prp | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Gwwjjnny | Ptdgfxg | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Bgtxsfbml | Klqxtd | $118.7 Bil | |||
| Moderna Inc
MRNA
| Dmdxkwyc | Cwpv | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Fbtjpbgts | Cykjj | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Mdmdljq | Xtzd | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Cllzvxlb | Qzn | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Xymxcfvl | Xrgbly | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Yqlndrsts | Mffw | $15.0 Bil | |||
| Incyte Corp
INCY
| Zfnlwcvf | Ppxsvx | $13.5 Bil |